WT Financial reports 1H23 earnings boost



WT Financial Group has reported operating profit (EBITDA) of $2.58 million over the first half of the 2023 financial year (1H23), up 55% from $1.67 million in 1H22.
Total revenue grew 144%, from $34.1 million to $83.3 million as at 31 December, 2022.
This was offset by a spike in the direct cost of sales, up 147% from $30.4 million in 1H22 to $75.2 million.
The group’s total operating expenses rose 90%, from $2.9 million to $5.5 million.
Accordingly, WT Financial's net profit before tax (NPBT) increased to just under $2 million, up 61% from $1.2 million in the previous corresponding period.
The group delivered a franking credit balance exceeding $1.4 million, and reported a cash balance totalling $4 million as at 31 December, 2022, up 185% from $1.4 million.
WT Financial Group chief executive, Keith Cullen, attributed the underlying result to the company’s acquisition strategy and its work “integrating and streamlining” operations of its acquisitions.
This included the purchase of Synchron in March 2022, and Perth-based Sentry Group — expanding the company’s financial adviser network to approximately 600.
“The efficiencies we have gained through the acquisition and integration of both Sentry and Synchron are enabling us to deliver an industry leading offering to advice practices as our industry continues to modernise and as consumer demands for advice grows,” he said.
Recommended for you
With wealth management M&A appetite only growing stronger, Business Health has outlined the major considerations for buyers and sellers to prevent unintended misalignment between the parties.
Industry body SIAA has said the falling number of financial advisers in Australia is a key issue impacting the attractiveness and investor participation of both public and private markets.
As advisers risk losing two-thirds of FUA during the $3.5 trillion wealth transfer, two co-founders underscore why fostering trust with the next generation is vital to retaining intergenerational wealth.
As advisers seek greater insights into FSCP determinations, what are the various options considered by the panel and can a decision be appealed?